Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 1, 1999, Pages 17-23

  Colao, Annamaria ^a   Cuocolo, Alberto ^a   Marzullo, Paolo ^a   Nicolai, Emanuele ^a   Ferone, Diego ^a   Florimonte, Luigia ^a   Salvatore, Marco ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; EXERCISE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HEART SCINTISCANNING; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL;

EID: 0032956615     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.1.5368     Document Type: Article

References (31)

1. 1. Morvan D, Komajda M, Grimaldi A, Turpin G, Grosgogeat Y. 1991 Cardiac hypertrophy and function in asymptomatic acromegaly. Eur Heart J. 12:666-672.
2. 2. Fazio S, Cittadini A, Sabatini D, et al. 1993 Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J. 14:26-33.
3. 3. Bertoni PD, Morandi G. 1987 Impaired left ventricular diastolic function in acromegaly: an echocardiographic study. Acta Cardiol. 42:1-10.
4. 4. Rodrigues EA, Caruana MP, Lahiri A, Nabarro JDN, Jacobs HS, Raftery EB. 1989 Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br Heart J. 62:185-194.
5. 5. Sicolo N, Bui F, Sicolo M, et al. 1993 Acromegalic cardiopathy: a left ventricular scintigraphic study. J Endocrinol Invest. 16:123-127.
6. 6. Lombardi G, Colao A, Marzullo P, et al. 1997 Is growth hormone bad for your heart: cardiovascular impact of GH deficiency and excess. J Endocrinol. 155:S33-S37.
7. 7. Lombardi G, Colao A, Cuocolo A, et al. 1997 Cardiological aspects of growth hormone and insulin-like growth factor-1. J Pediatr Endocrinol Metab. 10:553-560.
8. 8. Saccà L, Cittadini A, Fazio S. 1994 Growth hormone and the heart. Endocr Rev15:555-573.
9. 9. Fazio S, Cittadini A, Cuocolo A, et al. 1993 Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab. 79:441-446.
10. 10. Cuocolo A, Nicolai A, Fazio S, et al. 1995 Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography. J Nucl Med. 36:196-201.
11. 11. Löpez-Velasco R, Escobar-Morreale HF, Vega B, et al. 1997 Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab. 82:1047-1053.
12. 12. Colao A, Merola B, Ferone D, Lombardi G. 1997 Acromegaly. J Clin Endocrinol Metab. 82:2777-2781.
13. 13. Thuesen L, Christensen SE, Weeke J, Ørskov H, Henningsen P. 1989 The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf). 30:619-625.
14. 14. Chanson P, Timsit J, Masquet C, et al. 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:921-925.
15. 15. Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, et al. 1991 Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest. 14:17-23.
16. 16. Merola B, Cittadini A, Colao A, et al. 1993 Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 77:790-793.
17. 17. Lombardi G, Colao A, Ferone D, et al. 1996 Cardiovascular aspects in acromegaly: effects of treatment. Metabolism. 45(Suppl 1):57-60.
18. 18. Colao A, Ferone D, Lastoria S, et al. 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 81:2356-2362.
19. 19. Bonow RO, Bacharach SL, Green MV, et al. 1981 Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation. 64:315-323.
20. 20. Bacharach SL, Green MV, Borer JS, Hyde JE, Farkas SP, Johnston GS. 1979 Left ventricular peak ejection rate, filling rate and ejection fraction: frame requirements at rest and exercise. J Nucl Med. 20:1889-1893.
21. 21. Bonow RO, Vitale DF, Bacharach SL, Frederick TM, Kent KM, Green MV. 1985 Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation. 71:297-307.
22. 22. Arrighi JA, Soufer R. 1995 Left ventricular diastolic function: physiology methods of assessment and clinical significance. J Nucl Cardiol. 2:525-543.
23. 23. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71-79.
24. 24. Nabarro JDN. 1987 Acromegaly. Clin Endocrinol (Oxf). 26:481-512.
25. 25. Bengtsson BA, Edén S, Ernest I, Oden A, Sjögren B. 1988 Epidemiology and long term survival in acromegaly. Acta Med Scand. 223:327-335.
26. 26. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. 1996 Octreotide. N Engl J Med. 34:246-254.
27. 27. Melmed S, Dowling RH, Frohman LA, et al. 1994 Consensus statement: benefits vs. risks of medical therapy for acromegaly. Am J Med. 97:468-473.
28. 28. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293-299.
29. 29. Rajasoorya C. Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102.
30. 30. Colao A, Ferone D, Cappabianca P, et al. 1997 Effect of octreotide pre-treatment on surgical outcome in acromegaly. J Clin Endocrinol Metab. 82:3308-3314.
31. 31. Padayatty SJ, Perrins EJ, Belchetz PE. 1996 Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol. 134:554-559.